Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for detecting and evaluating antiviral infection activity

An anti-viral and active technology, applied in the field of antibody engineering and anti-viral medicine, can solve the problems of the application efficiency and value of cell infection models and animal protection models yet to be observed, no cell infection and animal protection models, etc., and the operation process is simple. , the results have good repeatability

Active Publication Date: 2016-07-13
FUDAN UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the cell infection model and animal protection model have been successfully applied to the research of some viruses, such as HIV and HCV, but due to the limitations of the culture and infection conditions of the extracorporeal cell infection system and the heterogeneity of the animal model, the cell infection model and The practical application efficiency and value of the animal protection model remains to be seen
In addition, there are no corresponding cell infection and animal protection models for some virus infections with high species, tissue and cell specificity, such as HBV infection, as well as some new and sudden infection viruses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for detecting and evaluating antiviral infection activity
  • A method for detecting and evaluating antiviral infection activity
  • A method for detecting and evaluating antiviral infection activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Anti-infective ability of HBV monoclonal antibody and HBIG

[0047] The antiviral activities of the HBV monoclonal antibody and HBIG were detected respectively by using the detection method established in the present invention. HBIG is the human anti-hepatitis B virus globulin produced by Zhongsheng Group, and the humanized anti-hepatitis B virus monoclonal antibody is provided by the Institute of Viral Disease Prevention and Control, Chinese Center for Disease Control and Prevention.

[0048] The specific detection steps are:

[0049] (1) Take isolated blood samples and separate to obtain serum samples of pathogens;

[0050] (2) After mixing the pathogen serum sample with reagent A and reagent B at a ratio of 1:4.5:4.5, add 0.5% Volume test molecules (divided into HBV monoclonal antibody group and HBIG group);

[0051] (3) Stand at room temperature for 3 hours, then centrifuge at 10,000 rpm for 30 minutes;

[0052] (4) The supernatant of the centrifuged m...

Embodiment 2

[0055] Example 2: The antiviral ability of HBIG and anti-HBV monoclonal antibody is related to the formation and deposition of viral complexes

[0056] figure 2 It is the result of the sedimentation specificity experiment.

[0057] Viral DNA was detected according to the method of Example 1, except that serum samples were treated with HBV monoclonal antibody and HBIG without sedimentation treatment, and viral DNA was detected.

[0058] The experimental results showed that the HBV monoclonal antibody BC1 and HBIG in the non-sedimentation treatment group could not clear the virus from the serum. The formation and detection of sedimentary virus complexes are necessary conditions for detection.

Embodiment 3

[0059] Embodiment 3 Specificity experiment of human HBV monoclonal antibody BC1

[0060] image 3 It is a specific experiment for human HBV monoclonal antibody BC1.

[0061] Viral DNA was detected according to the method in Example 1.

[0062] The results showed that the ability of HBV monoclonal antibody to neutralize the virus was 93% (P=0.0001), which was not significantly different from the ability of HBIG to neutralize the virus. The virus clearance ability of HBIG and anti-HBV monoclonal antibody BC1 was specific compared with human serum albumin control.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of antibody engineering and antiviral medicine, and relates to a method for rapidly and effectively measuring the antiviral function of recombinant human anti-hepatitis B virus antibody. The invention utilizes the technology of sinking virus complexes to establish a new method for detecting and evaluating the anti-virus ability of molecules. The method is to detect the anti-virus and anti-infection ability of the molecule by detecting the ability of the test molecule to induce a sinking pathogenic complex in serum; the pathogen is a virus. The method can be used to quickly detect the ability of antibodies and other anti-infection drugs to clear virus and control virus infection. The method is simple to operate and the results are reproducible, and it is a supplement to the existing antiviral drug functional detection and evaluation methods. a new choice. The invention also relates to a detection reagent for antiviral infection activity, a sinking pathogenic complex occurring in the detection process and the application of the above detection method.

Description

technical field [0001] The invention relates to the fields of antibody engineering and antiviral medicine, in particular to a method for rapidly and effectively measuring the antiviral function of recombinant human anti-hepatitis B virus antibody. Background technique [0002] Human hepatitis B virus (human hepatitis B virus, HBV) infection is a global public health problem. According to the statistics of the World Health Organization (World Health Organization, WHO), more than 2 billion people have been infected with HBV worldwide, of which 350 million are positive. Suffering from chronic HBV infection (WHO, 2000). my country is a high-incidence area of ​​hepatitis B. The 2006 national viral hepatitis serum epidemiological survey data showed that the positive rate of hepatitis B surface antigen (HBsAg) in the whole population was 7.18 %. Based on this, it is estimated that 93 million people in my country are HBV carriers, of which 30 million are patients with chronic hepatiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/70C12Q1/68
Inventor 陈力闻玉梅王蕾谢幼华梁米芳
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com